# Optimum Immunosuppression in Renal Transplant Recipients.New Onset Diabetes After Transplantation

> **NCT01002339** · PHASE4 · TERMINATED · sponsor: **Armando Torres Ramírez** · enrollment: 134 (actual)

## Conditions studied

- Diabetes Mellitus, Adult-Onset

## Interventions

- **DRUG:** Tacrolimus with rapid steroid withdrawal
- **DRUG:** Tacrolimus with steroids minimization
- **DRUG:** CsA with steroid minimization

## Key facts

- **NCT ID:** NCT01002339
- **Lead sponsor:** Armando Torres Ramírez
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-02
- **Primary completion:** 2014-02
- **Final completion:** 2015-06
- **Target enrollment:** 134 (ACTUAL)
- **Why stopped:** Terminated: higher rate of acute rejection in the Cyclosporin A group
- **Last updated:** 2024-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01002339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01002339, "Optimum Immunosuppression in Renal Transplant Recipients.New Onset Diabetes After Transplantation". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT01002339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*